more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

Top 28% (71 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline

by Zacks Equity Research Published on July 22,2020

The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline

Top Stock Reports for Bank of America, Abbott & Chevron

by Sheraz Mian Published on July 21,2020

Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Abbott Laboratories (ABT) and Chevron (CVX).

Logitech (LOGI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on July 17,2020

A strong Video Collaboration business is expected to have driven Logitech's (LOGI) first-quarter fiscal 2021 results. However, weak Mobile Speakers segment is likely to have remained an overhang.

Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid

by Zacks Equity Research Published on July 16,2020

Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.

Abbott (ABT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on July 16,2020

Abbott (ABT) delivered earnings and revenue surprises of 32.56% and 7.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ABTPositive Net Change

5 Earnings Charts for the Coronavirus Recovery

by Tracey Ryniec Published on July 15,2020

Drug makers, restaurants, industrials and transports will tell you what is really going on in the US economy.

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research Published on July 15,2020

The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.

OrganiGram (OGI) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research Published on July 14,2020

OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and product launches in the fiscal third quarter despite pandemic-hit business conditions.

Why Earnings Season Could Be Great for Abbott (ABT)

by Zacks Equity Research Published on July 14,2020

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ABTPositive Net Change

Aphria (APHA) Looks Good: Stock Adds 8.8% in Session

by Zacks Equity Research Published on July 14,2020

Aphria (APHA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

What's in Store for Taiwan Semiconductor's (TSM) Q2 Earnings?

by Zacks Equity Research Published on July 13,2020

Taiwan Semiconductor's (TSM) second-quarter results are likely to reflect robust technology portfolio and 5G deployment amid coronavirus pandemic.

semiconductor

The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

by Zacks Equity Research Published on July 13,2020

The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

Infosys (INFY) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research Published on July 13,2020

While Infosys' (INFY) Q1 performance is likely to have benefited from the ongoing digital transformations and large deal wins, elevated expenses might have hurt the bottom line.

Top Analyst Reports for Oracle, Abbott & Chevron

by Sheraz Mian Published on July 10,2020

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Abbott Laboratories (ABT) and Chevron (CVX).

Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on July 09,2020

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABTPositive Net Change

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on July 09,2020

Is (ABT) Outperforming Other Medical Stocks This Year?

ABTPositive Net Change

Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes

by Zacks Equity Research Published on July 09,2020

Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.

medical

LabCorp Launches At-Home Coronavirus Test Collection Kit

by Zacks Equity Research Published on July 08,2020

LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.

medical

Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?

by Zacks Equity Research Published on July 07,2020

Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.